QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-is-agios-pharmaceuticals-stock-sinking-today

Agios stock drops as mitapivat's Phase 3 trial shows strong hemoglobin gains but limited impact on sickle cell pain crises,...

 agios-pharmaceuticals-says-topline-results-from-rise-up-phase-3-trial-of-mitapivat-for-sickle-cell-disease-met-its-primary-endpoint-of-hemoglobin-response-while-mitapivat-did-not-achieve-statistical-significance-on-the-annualized-rate-of-sickle-cell-pain-crises-compared-to-placebo

Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentrati...

 agios-pharmaceuticals-q3-eps-178-beats-191-estimate-sales-12880m-beat-10417m-estimate

Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.78) per share which beat the analyst consensus estimate of...

 reported-earlier-agios-pharmaceuticals-receives-chmps-opinion-for-the-new-indication-for-pyrukynd-the-european-commission-will-now-review-the-chmps-opinion-with-the-final-decision-expected-by-early-2026

CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceut...

 hc-wainwright--co-reiterates-buy-on-agios-pharmaceuticals-maintains-56-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and maintains $56 pri...

 fda-delays-decision-on-agios-pharmaceuticals-blood-disorder-drug-for-expanded-use

Agios' Pyrukynd FDA review for thalassemia delayed to Dec. 7, 2025, after REMS submission addressing potential liver injury...

 saudi-food-and-drug-authority-approves-agios-pyrukynd-for-adults-with-thalassemia

First regulatory approval for PYRUKYND in thalassemia, evaluated under SFDA's Breakthrough Medicines ProgramAgios partnered...

 agios-pharmaceuticals-says-it-is-aware-of-the-securities-analyst-report-published-on-august-4-2025-detailing-recent-pyrukynd-data-from-the-us-fda-adverse-event-reporting-system-co-is-committed-to-delivering-safe-effective-treatments-for-patients-with-rare-diseases-and-will-continue-to-follow-our-established-rigorous-pharmacovigilance-processes-separately-on-august-4-2025-the-saudi-food-and-drug-authority-announced-that-it-has-approvedpyrukynd

-SEC Filing

 agios-pharmaceuticals-q2-eps-193-misses-177-estimate-sales-12455m-beat-9537m-estimate

Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.93) per share which missed the analyst consensus estimate ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION